Key facts
- This page summarizes David M. Mott's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 01 Jul 2024, 17:04.
David M. Mott - 01 Jul 2024 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Director
- Issuer ticker
- ADAP
- Reported as of
- 01 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2024, 17:04:22 UTC
- Prior SEC filing
- 17 Jun 2024
- Next SEC filing
- 14 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David M. Mott
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David M. Mott filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 01 Jul 2024.
Change
- Previous filing in this sequence was filed on 17 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADAP
transaction
Derivative
Option to purchase Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +1,583,214
- Change %
- Price
- $0.000000
- Shares after
- 1,583,214
- Date
- 01 Jul 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,583,214
- Exercise price
- $0.1600
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The exercise price was converted from GBP0.13 based on an exchange rate of $U.S. 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount.